Clinical Trials

40 enrolled

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT05112601 2026-03-18

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

81 enrolled

Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

NCT06029270 2026-03-18

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

156 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06064097 2026-03-18

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Head & Neck

Nasopharyngeal Carcinoma

NCT06325683 2026-03-18

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

184 enrolled

CNS

Glioblastoma

NCT05136196 2026-03-17

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

150 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

270 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06863311 2026-03-16

EXACT

70 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03258567 2026-03-06

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

40 enrolled

Lymphoid

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT03026140 2026-03-05

NICHE

353 enrolled

Colonic Neoplasms

NCT03297606 2026-03-04

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06523621 2026-03-04

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Plasma cell

Multiple Myeloma

NCT07246863 2026-03-04

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Other solid neoplasmThoracic

131 enrolled

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06275360 2026-03-02

RIVAL

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

180 enrolled

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT06946797 2026-02-24

CheckMate-1533

76 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07188896 2026-02-23

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

120 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06999980 2026-02-19

Neo IRENIE

494 enrolled

Melanoma

NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

20 enrolled

Carcinoma, Merkel Cell

NCT02693535 2026-02-13

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07230613 2026-02-11

NEOREM-NEO-1

Melanoma

NCT06534190 2026-02-09

CD8 PET Imaging in Metastatic Solid Tumours

30 enrolled

Other solid neoplasm

Locally Advanced Solid Tumor

NCT06624475 2026-02-05

NEON

30 enrolled

Carcinoma, Basal Cell

NCT03340129 2026-02-02

ABC-X

218 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04562129 2026-01-29

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

29 enrolled

Melanoma, Skin Neoplasms

NCT06365619 2026-01-29

NeoRelapse

25 enrolled

Melanoma

NCT05502315 2026-01-23

CANOPY

47 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06948448 2026-01-21

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

144 enrolled

Colorectal Neoplasms

NCT05327686 2026-01-14

SAMURAI

240 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05704647 2026-01-14

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

30 enrolled

Melanoma

NCT05317000 2026-01-12

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06295159 2026-01-08

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

90 enrolled

Melanoma

NCT05779423 2026-01-06

Cryoablation+Ipilimumab+Nivolumab in Melanoma

37 enrolled

Melanoma, Skin Neoplasms

NCT05428007 2026-01-05

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

105 enrolled

Melanoma

NCT04933903 2025-12-30

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07226856 2025-12-22

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

43 enrolled

Pancreatic Neoplasms

NCT04966663 2025-12-18

ctDNA Lung RCT

66 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05257590 2025-12-17

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

95 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT06265285 2025-12-04

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT05263050 2025-12-03

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

EndocrineGenitourinaryNET

111 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT06319196 2025-12-03

ClearMe

54 enrolled

Melanoma

NCT06941857 2025-12-03

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

20 enrolled

Carcinoma, Pancreatic Neoplasms

NCT07155317 2025-11-12

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

99 enrolled

Melanoma

NCT07223424 2025-11-10

PSI-Immune